FDA Approves Bristol Myers Squibb's Camzyos As First Treatment For Children With Obstructive Hypertrophic Cardiomyopathy Weighing At Least 30 kg

The FDA has approved Bristol Myers Squibb's drug Camzyos as the first treatment for children weighing at least 30 kg with obstructive hypertrophic cardiomyopathy. This approval marks a significant advancement in addressing the functional capacity and symptoms of this rare inherited heart condition. The approval could potentially impact the company's revenue and market position in the pediatric cardiology sector.